Dose-escalation in prostate cancer : Results of randomized trials
Copyright © 2022 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved..
In 1998, an editorial from the International Journal of Radiation Oncology - Biology - Physics (IJROBP) on the occasion of the publication of Phase I by Zelefsky et al. on 3D radiotherapy dose escalation asked the question: "will more prove better?". More than 20 years later, several prospective studies have supported the authors' conclusions, making dose escalation a new standard in prostate cancer. The data from prospective randomized studies were ultimately disappointing in that they failed to show an overall survival benefit from dose escalation. However, there is a clear and consistent benefit in biochemical recurrence-free survival, which must be weighed on an individual patient basis against the potential additional toxicity of dose escalation. Techniques and concepts have become more and more precise, such as intensity modulated irradiation, simultaneous integrated boost, hypofractionated dose-escalation, pelvic irradiation with involved node boost or focal dose-escalation on gross recurrence after prostatectomy. The objective here was to summarize the prospective data on dose escalation in prostate cancer and in particular on recent advances in the field. In 2022, can we finally say that more has proven better?.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique - 26(2022), 6-7 vom: 24. Okt., Seite 899-904 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kissel, M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Brachytherapy |
|---|
| Anmerkungen: |
Date Completed 20.09.2022 Date Revised 20.09.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.canrad.2022.07.011 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM345476336 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM345476336 | ||
| 003 | DE-627 | ||
| 005 | 20231226025136.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.canrad.2022.07.011 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1151.xml |
| 035 | |a (DE-627)NLM345476336 | ||
| 035 | |a (NLM)36030191 | ||
| 035 | |a (PII)S1278-3218(22)00163-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kissel, M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dose-escalation in prostate cancer |b Results of randomized trials |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.09.2022 | ||
| 500 | |a Date Revised 20.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a In 1998, an editorial from the International Journal of Radiation Oncology - Biology - Physics (IJROBP) on the occasion of the publication of Phase I by Zelefsky et al. on 3D radiotherapy dose escalation asked the question: "will more prove better?". More than 20 years later, several prospective studies have supported the authors' conclusions, making dose escalation a new standard in prostate cancer. The data from prospective randomized studies were ultimately disappointing in that they failed to show an overall survival benefit from dose escalation. However, there is a clear and consistent benefit in biochemical recurrence-free survival, which must be weighed on an individual patient basis against the potential additional toxicity of dose escalation. Techniques and concepts have become more and more precise, such as intensity modulated irradiation, simultaneous integrated boost, hypofractionated dose-escalation, pelvic irradiation with involved node boost or focal dose-escalation on gross recurrence after prostatectomy. The objective here was to summarize the prospective data on dose escalation in prostate cancer and in particular on recent advances in the field. In 2022, can we finally say that more has proven better? | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Brachytherapy | |
| 650 | 4 | |a Cancer de la prostate | |
| 650 | 4 | |a Curiethérapie | |
| 650 | 4 | |a Dose escalation | |
| 650 | 4 | |a Escalade de dose | |
| 650 | 4 | |a Prostatic neoplasms | |
| 650 | 4 | |a Radiotherapy | |
| 650 | 4 | |a Radiothérapie | |
| 700 | 1 | |a Krhili, S-L |e verfasserin |4 aut | |
| 700 | 1 | |a Minsat, M |e verfasserin |4 aut | |
| 700 | 1 | |a El Ayachy, R |e verfasserin |4 aut | |
| 700 | 1 | |a Bringer, S |e verfasserin |4 aut | |
| 700 | 1 | |a Lahmi, L |e verfasserin |4 aut | |
| 700 | 1 | |a Porte, J |e verfasserin |4 aut | |
| 700 | 1 | |a Labib, A |e verfasserin |4 aut | |
| 700 | 1 | |a Graff, P |e verfasserin |4 aut | |
| 700 | 1 | |a Crehange, G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique |d 1998 |g 26(2022), 6-7 vom: 24. Okt., Seite 899-904 |w (DE-627)NLM092193420 |x 1769-6658 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2022 |g number:6-7 |g day:24 |g month:10 |g pages:899-904 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.canrad.2022.07.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2022 |e 6-7 |b 24 |c 10 |h 899-904 | ||